CXCL10 and melanoma: Additionally, low‐dose IT ADU‐S100 treatment increased the production of anti‐angiogenic (e.g., CXCL10 or vascular endothelial growth inhibitor) and tertiary lymphoid structure‐inducing factors (e.g., CCL19 and CCL21) in a B16‐F10 melanoma mouse model.[67] Treatment efficacy could be even more enhanced upon the combination of a STING agonist with an anti‐vascular endothelial growth factor receptor 2 (VEGFR2) antibody and either an anti‐PD‐1 or anti‐CTLA‐4 antibody compared to mono‐ or dual combination therapy in a colon cancer mouse model.[66]